61 Investor presentation First six months of 2024 Novo Nordisk has expanded affo to ~50 million people and SELECT ~50m people have Wegovy ® coverage in the US People with obesity (millions) 110.0 30.0 20.0 60.0 Prevalence Commercial 50.0 12.0 38.0 Access Medicaid and other 1.3 Full-year patients on NN AOMs in 2023 Medicare Part D AOM: Anti-obesity medications; CMS: Center for Medicare and Medicaid Services; CV:Cardiovascular disease; DoD: Department of D Source: Novo Nordisk Annual Report 2023, Internal analysis as per Q2 2024
Download PDF file